1-20 of 139
M. GOLDMAN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath
Journal: Blood
Blood (2015) 126 (23): 4024.
https://doi.org/10.1182/blood.V126.23.4024.4024
Published: 2015
Journal Articles

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Corinne Hedgley, BSc, Sarah Adams, BSc MSc, Letizia Foroni, MDPhD, Jane F. Apperley, MD, Tessa L Holyoake, MDPhDFRSE FMedSci, Christopher Pocock, MD PhD, Jenny L Byrne, MB ChB PhDFRCP FRCPath, Lynn Margaret Seeley, MSc RN NDN, Wendy L Osborne, MBBS(Hons) MRCP FRCPath, John M Goldman, DM, Mhairi Copland, BSc PhDFRCP FRCPath, Richard E Clark, MA, MD
Journal: Blood
Blood (2014) 124 (21): 517.
https://doi.org/10.1182/blood.V124.21.517.517
Published: 2014
Journal Articles

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Mary Alikian, Peter Ellery, Matrin Forbes, Gareth Gerrard, PhD, Tim Aitman, Dalia Kasperaviciute, Dragana Milojkovic, PhD, David Marin, MD, John M Goldman, MD, Jane F Apperley, MD, Letizia Foroni, MD, Alistair Reid, PhD
Journal: Blood
Blood (2013) 122 (21): 4006.
https://doi.org/10.1182/blood.V122.21.4006.4006
Published: 2013
Journal Articles

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Javier Pinilla-Ibarz, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Philipp D. Le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2013) 122 (21): 4007.
https://doi.org/10.1182/blood.V122.21.4007.4007
Published: 2013
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D. le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F. Apperley, MD, H Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, Frank G. Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M. Goldman, MD, Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2738.
https://doi.org/10.1182/blood.V122.21.2738.2738
Published: 2013
Journal Articles

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Philipp D. Le Coutre, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Kumiko Yanase, MD, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 1496.
https://doi.org/10.1182/blood.V122.21.1496.1496
Published: 2013
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Andreas Hochhaus, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, François Guilhot, MD
Journal: Blood
Blood (2013) 122 (21): 1498.
https://doi.org/10.1182/blood.V122.21.1498.1498
Published: 2013
Journal Articles

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, François Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 650.
https://doi.org/10.1182/blood.V122.21.650.650
Published: 2013
Journal Articles

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Michael W. Deininger, MD, PhD, Neil P. Shah, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Franck E. Nicolini, MD, PhD, Moshe Talpaz, MD, Michele Baccarani, MD, Martin C Muller, MD, Jin Li, Stephanie Lustgarten, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Francois Guilhot, MD, John M Goldman, DM, Hagop M. Kantarjian, MD, Simona Soverini, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD
Journal: Blood
Blood (2013) 122 (21): 652.
https://doi.org/10.1182/blood.V122.21.652.652
Published: 2013
Journal Articles

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Christopher J. Walker, Joshua J. Oaks, Ramasamy Santhanam, Paolo Neviani, Jason G. Harb, Gregory Ferenchak, Justin J. Ellis, Yosef Landesman, Ann-Kathrin Eisfeld, Nash Y. Gabrail, Carrie L. Smith, Michael A. Caligiuri, Peter Hokland, Denis Claude Roy, Alistair Reid, Dragana Milojkovic, John M. Goldman, Jane Apperley, Ramiro Garzon, Guido Marcucci, Sharon Shacham, Michael G. Kauffman, Danilo Perrotti
Journal: Blood
Blood (2013) 122 (17): 3034–3044.
https://doi.org/10.1182/blood-2013-04-495374
Published: 2013
Includes: Supplemental data
Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Joshua J. Oaks, Ramasamy Santhanam, Christopher J. Walker, Steve Roof, Jason G. Harb, Greg Ferenchak, Ann-Kathrin Eisfeld, James R. Van Brocklyn, Roger Briesewitz, Sahar A. Saddoughi, Kyosuke Nagata, Robert Bittman, Michael A. Caligiuri, Omar Abdel-Wahab, Ross Levine, Ralph B. Arlinghaus, Alfonso Quintas-Cardama, John M. Goldman, Jane Apperley, Alistair Reid, Dragana Milojkovic, Mark T. Ziolo, Guido Marcucci, Besim Ogretmen, Paolo Neviani, Danilo Perrotti
Journal: Blood
Blood (2013) 122 (11): 1923–1934.
https://doi.org/10.1182/blood-2013-03-492181
Published: 2013
Includes: Supplemental data
Journal Articles

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani, Michael W. Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jorge E. Cortes, François Guilhot, Henrik Hjorth-Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong-Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles Schiffer, Richard Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann
Journal: Blood
Blood (2013) 122 (6): 872–884.
https://doi.org/10.1182/blood-2013-05-501569
Published: 2013
Includes: Supplemental data
Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ron Paquette, MD, PhD, Charles Chuah, MD, Franck E Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M Kantarjian, M.D., The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 163.
https://doi.org/10.1182/blood.V120.21.163.163
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Dong-Wook Kim, Jorge E. Cortes, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3749.
https://doi.org/10.1182/blood.V120.21.3749.3749
Published: 2012
Journal Articles

Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?

Pratap Neelakantan, MRCP, Dragana Milojkovic, Gareth Gerrard, PhD, Letizia Foroni, Jane Apperley, Richard M Szydlo, Alistair Reid, PhD, Marco Bua, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin
Journal: Blood
Blood (2012) 120 (21): 3760.
https://doi.org/10.1182/blood.V120.21.3760.3760
Published: 2012
Journal Articles

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Andreas Hochhaus, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, Martin C Muller, MD, Carlo Gambacorti-Passerini, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3763.
https://doi.org/10.1182/blood.V120.21.3763.3763
Published: 2012
Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, FACP, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, David J. Dorer, Ronald Keith Knickerbocker, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3747.
https://doi.org/10.1182/blood.V120.21.3747.3747
Published: 2012
Journal Articles

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Jacob Grinfeld, Juan M Alonso-Dominguez, Mary Alikian, Mikel Valgañón, PhD, Georgios Nteliopoulos, PhD, Deborah L. White, PhD, FFSc(RCPA), David Marin, Corinne Hedgley, Stephen O'Brien, Richard E. Clark, MD, Richard M Szydlo, Jane Apperley, John M Goldman, MD, Letizia Foroni, Gareth Gerrard, PhD
Journal: Blood
Blood (2012) 120 (21): 2555.
https://doi.org/10.1182/blood.V120.21.2555.2555
Published: 2012
Journal Articles

Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.

Frederick Pimm, Richard Szydlo, PhD, Letizia Foroni, Francesco Dazzi, MD, Jaspal S Kaeda, PhD, Gareth Gerrard, PhD, Alistair Reid, PhD, Mikel Valganon, BSc, Edward J Kanfer, John M Goldman, MD, Dragana Milojkovic, David Marin, Jane Apperley
Journal: Blood
Blood (2012) 120 (21): 2789.
https://doi.org/10.1182/blood.V120.21.2789.2789
Published: 2012
Journal Articles

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

Pratap Neelakantan, MRCP, Gareth Gerrard, PhD, Letizia Foroni, Dragana Milojkovic, Jane Apperley, Richard Szydlo, PhD, Marco Bua, Alistair G Reid, BSc, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin
Journal: Blood
Blood (2012) 120 (21): 68.
https://doi.org/10.1182/blood.V120.21.68.68
Published: 2012